Skip to main content
PMC home page
Scientific Reports logoLink to Scientific Reports
. 2016 Feb 2;6:20300. doi: 10.1038/srep20300

Icaritin requires Phosphatidylinositol 3 kinase (PI3K)/Akt signaling to counteract skeletal muscle atrophy following mechanical unloading

Zong-Kang ZHANG 1,*, Jie LI 1,*, Jin LIU 2, Baosheng GUO 2, Albert LEUNG 1,a, Ge ZHANG 2,b, Bao-Ting ZHANG 1,c
PMCID: PMC4735824  PMID: 26831566

Abstract

Counteracting muscle atrophy induced by mechanical unloading/inactivity is of great clinical need and challenge. A therapeutic agent that could counteract muscle atrophy following mechanical unloading in safety is desired. This study showed that natural product Icaritin (ICT) could increase the phosphorylation level of Phosphatidylinositol 3 kinase (PI3K) at p110 catalytic subunit and promote PI3K/Akt signaling markers in C2C12 cells. This study further showed that the high dose ICT treatment could significantly attenuate the decreases in the phosphorylation level of PI3K at p110 catalytic subunit and its downstream markers related to protein synthesis, and inhibit the increases in protein degradation markers at mRNA and protein levels in rat soleus muscle following 28-day hindlimb unloading. In addition, the decreases in soleus muscle mass, muscle fiber cross-sectional area, twitch force, specific force, contraction time and half relaxation time could be significantly attenuated by the high dose ICT treatment. The low dose ICT treatment could moderately attenuate the above changes induced by unloading. Wortmannin, a specific inhibitor of PI3K at p110 catalytic subunit, could abolish the above effects of ICT in vitro and in vivo, indicating that PI3K/Akt signaling could be required by ICT to counteract skeletal muscle atrophy following mechanical unloading.

Skeletal muscles respond to the stimulus of mechanical load for growth and maintenance. Muscle atrophy occurs during the periods of decreased mechanical loading1,2,3,4,5. The known consequences are loss of muscle mass, decrease in muscle strength and increase in fatigue6. Losses of muscle mass and strength decrease the ability to maintain posture and perform a wide range of movements and motions, reduce bone strength7 and increase the risk of fractures, incidence of death8 and physical frailty9. Counteracting muscle atrophy associated with mechanical unloading/inactivity is of great clinical need and challenge. In the past years, physical therapies, such as resistance exercise10 and electrical stimulation11, are attempted to attenuate muscle atrophy. However, low compliance of patients limits their use of physical therapies. Recently, pharmacological agents, such as insulin-like growth factor-I (IGF-I)12, anabolic androgenic steroids13, myostatin inhibitors14, and β2-adrenergic agonists15, have been also tested to counteract muscle atrophy. But, it should be pointed out that potential risks of drug resistance, cardiovascular and prostate cancer and cardiac hypertrophy/dysfunction16,17, are the bottleneck for their clinical translation. It is desirable to develop an alternative therapeutic agent that could counteract muscle atrophy following mechanical unloading in safety.

Phosphatidylinositol 3 kinase (PI3K)/Akt signaling pathway is critical for regulating the balance between protein synthesis and degradation during disuse/inactivity-induced muscle atrophy18. Deactivation of PI3K/Akt pathway not only leads to decreased protein synthesis, but causes increase in protein degradation rate, resulting in muscle atrophy19. Epimedium, a traditional Chinese herb, has been widely used for both maintaining musculoskeletal function and treating musculoskeletal disorders in safety in China for over 2000 years20. Our randomized, double-blind and placebo-controlled clinical trial supervised in late postmenopausal women has shown that oral administration of Epimedium-derived flavonoids (EF) for 24 months has no dominant side effects on the major systems, including cardiovascular, reproductive, digestive, and nervous systems21, and there is no evidence showing that EF has the potential risk of drug resistance. Icariin is the most abundant active component in Epimedium22,23. Icaritin (ICT), an intestinal metabolite of EF, has demonstrated many pharmacological and biological activities (Fig. 1A)22,23,24,25,26. It has been reported ICT could cause significant activation of the serine/threonine kinase Akt in human lung epithelial cells27. Several studies show that icariin, which has parallel biological activities to ICT, can increase the phosphorylation (activation) of Akt in PC12 (pheochromocytoma) cells28, endothelial progenitor cells29, rat bone marrow stromal cells30, and lipopolysaccharide (LPS)-stimulated macrophages31. Administration of LY294002 or wortmannin, specific inhibitors of PI3K, could significantly inhibit the effect of ICT or icariin treatment27,28,29,30,31, suggesting that PI3K/Akt signaling pathway might be involved in various biological effects of ICT. These clues inspire a hypothesis that ICT could require PI3K/Akt signaling pathway to counteract skeletal muscle atrophy induced by mechanical unloading.

Figure 1. Chemical structure of ICT and effect of ICT on PI3K/Akt signaling in C2C12 cells.

Figure 1

Open in a new tab

(A) Chemical structure of ICT. (B) Representative Western blots and corresponding densitometry data illustrated the expression levels of phosphorylated and total protein (PI3K-p110, Akt, mTOR, p70S6K, and 4EBP1) in C2C12 cells. (C) Representative Western blots and corresponding densitometry data illustrated the nuclear and total cell FOXO1 and FOXO3a protein levels in C2C12 cell lysis. (D) Real-time PCR detected the mRNA levels of Atrogin-1 (left) and MuRF-1 (right) in C2C12 cells. Data are presented as mean ± SEM. *for P < 0.05 vs. Control. GAPDH served as the endogenous control. Each sample was assessed in triplicate.

In the present study, we investigated the effect of ICT with or without PI3K inhibitor on protein synthesis/degradation, PI3K/Akt signaling pathway, muscle type distribution, histomorphology and mechanical function in skeletal muscles during mechanical unloading.

Results

Effect of ICT on PI3K/Akt signaling in C2C12 cells

The C2C12 myoblasts were cultured and treated with 5 μM, 10 μM and 20 μM ICT for 24 hours. The phosphorylated and total protein levels of PI3K at p110 catalytic subunit (PI3K-p110) and its downstream proteins, including Akt, the mammalian target of rapamycin kinase (mTOR), ribosomal protein S6 kinase (p70S6K) and eukaryotic translation initiation factor 4E binding protein 1 (4EBP1)32, were detected by Western blotting. The distribution of forkhead box O (FOXO) family transcription factors (FOXO1 and FOXO3a) in the nuclear fraction and total cell were also determined by western blotting. The mRNA levels of muscle atrophy F-box protein (Atrogin-1) and muscle RING finger protein 1 (MuRF-1) were examined by real-time PCR. Comparing to the Control Group, the phosphorylation level of PI3K-p110 in the C2C12 cells incubated with 5 μM, 10 μM and 20 μM ICT was 1.2-fold, 2.3-fold and 4.5-fold higher, respectively. Similar patterns were also observed in the phosphorylation levels of the downstream proteins of PI3K (Akt, mTOR, p70S6K and 4EBP1) (Fig. 1B). On the other hand, the expression levels of FOXO1 and FOXO3a in nuclei fraction in the ICT treatment groups (5–20 μM) were 10–35% lower than those in the Control Group in a dose-dependent manner (Fig. 1C). Similar data were also found in the mRNA levels of Atrogin-1 and MuRF-1 (Fig. 1D). In addition, the C2C12 cells were cultured and treated with 20 μM ICT for 1, 3, 5 and 7 days. Cell viability, morphology and myogenic markers (MyoD and myogenin) levels were determined by cell counting kit-8 (CCK-8) assay, cell morphology examination and Western blotting. The differentiation rate of C2C12 cells with ICT treatment was significantly higher than vehicle control (Supplementary Figure 1).

Involvement of PI3K-p110 catalytic subunit for effect of ICT in C2C12 cells

To further determine whether PI3K-p110 catalytic subunit is required for the ICT-induced activation of PI3K/Akt signaling in C2C12 cells, a specific inhibitor of PI3K at p110 catalytic subunit wortmannin (Wort, 5nM) was pre-incubated with C2C12 cells for 1 hour followed by the treatment with ICT (20 μM) (ICT+Wort Group) or routine culture medium (Wort Group) for further 24 hours. Cells only treated with ICT (20 μM) or routine culture medium served as the ICT Group or the Control Group, respectively. The phosphorylation levels of PI3K-p110 and its downstream proteins related to protein synthesis in the Wort Group were significantly lower than those in the Control Group. The phosphorylation levels of the proteins in the ICT+Wort Group were significantly lower than those in the ICT Group, but a little higher than those in the Wort Group (P  > 0.05). No significant differences were found between the ICT+Wort Group and the Control Group (Fig. 2A). Significantly higher expression levels of FOXO1 and FOXO3a in nuclei fraction were present in the Wort Group compared to the Control Group. The expression levels of FOXO1 and FOXO3a in nuclei fraction were significantly lowered in the ICT Group compared to the Control Group, which was obviously blocked in the ICT+Wort Group (P < 0.05). There were no significant differences between the ICT+Wort and the Control Group (Fig. 2B). Similar data were also found in the mRNA levels of Atrogin-1 and MuRF-1 (Fig. 2C).

Figure 2. Influence of PI3K inhibitor on ICT effect in C2C12 cells.

Figure 2

Open in a new tab

(A) Representative Western blots and corresponding densitometry data illustrated the expression levels of phosphorylated and total protein (PI3K-p110, Akt, mTOR, p70S6K, and 4EBP1) in C2C12 cells. (B) Representative Western blots and corresponding densitometry data illustrated the nuclear and total cell FOXO1 and FOXO3a protein levels in C2C12 cell lysis. (C) Real-time PCR detected the mRNA levels of Atrogin-1 (left) and MuRF-1 (right) in C2C12 cells. Data are presented as mean ± SEM. *for P < 0.05 vs. Control. + for P < 0.05 vs. ICT. GAPDH served as the endogenous control. Each sample was assessed in triplicate.

Effect of ICT treatment on muscle weight and muscle fiber cross-sectional area (CSA)

To investigate the effect of ICT treatment on unloading-induced skeletal muscle atrophy, two oral dosages of ICT (80 or 120mg/kg/day) were administered daily to 3-month old male Sprague-Dawley (SD) rats with or without daily injection of wortmannin (15 μg/kg/day) during 28-day hindlimb suspension (HS). The animals were assigned to eight groups including Baseline, Age-mateched Control, HS, Low-ICT, High-ICT, Wort, Low-ICT+Wort, and High-ICT+Wort groups as described in Materials & Methods. The muscle-to-body weight (mw/bw) ratio of soleus in the Age-matched Control Group was not changed when compared to the Baseline Group. After 28-day HS, the ratio showed a significant decrease from the baseline in the HS Group. The ratio in the Low-ICT Group was a little higher than that in the HS Group (P  > 0.05), whereas the ratio was significantly higher in the High-ICT Group than that in the HS Group. However, the ratio in the High-ICT Group was still significantly lower than that in the Baseline Group. In addition, the ratio in the Wort Group was not significantly different from that in the HS Group. Interestingly, the ratio was significantly lower in the High-ICT+Wort Group than that in the High-ICT Group (Fig. 3A). Similar pattern was also found in the results of muscle fiber CSA (Fig. 3B). There was no significant difference observed in the data of blood biochemical evaluation and histological analysis of the major organs among the HS, Low-ICT and High-ICT Groups (Supplementary Figure 2).

Figure 3. Effect of ICT on muscle mass and muscle fiber CSA.

Figure 3

Open in a new tab

(A) Soleus muscle-to-body weight ratio in each group. (B) Quantification of the soleus muscle fiber CSA (μM2). (C) Representative images of cross-sections from mid-belly soleus muscle stained by H&E. Scale bar, 100 μM. Data are presented as mean ± SEM. N = 10. *for P < 0.05 vs. Baseline. #for P < 0.05 vs. HS. + for P < 0.05 vs. High-ICT+Wort. Each sample was assessed in triplicate.

Effect of ICT treatment on muscle fiber type distribution

To identify the muscle fiber type distribution, the muscle myosin heavy chain (MHC) type I (slow-twitch type fibers), IIa (fast-twitch type fibers) and IIb (faster-twitch type fibers) were detected by immunohistochemistry staining. As shown in Fig. 4A, the majority of the muscle fiber type in soleus muscle was MHC I fiber. MHC IIb fiber was not detected in soleus muscle while hybrid MHC I/IIa fibers were observed in all groups. There was no significant difference in the proportion of the MHC I fiber between the Baseline Group and the Age-matched Control Group. After 28-day HS, the proportion of the MHC I fiber showed a significant decrease in the HS Group compared to the Baseline Group, while the proportion of the MHC IIa fiber increased instead when compared to the Baseline Group. The proportion of the MHC I fiber in the High-ICT Group was significantly higher than that in the HS Group, which was blocked by the wortmannin treatment (P < 0.05). The proportion of MHC I fiber in the Low-ICT Group was moderately higher than that in the HS Group (P > 0.05). There were no significant differences observed among three wortmannin-treated groups and the HS Group (Fig. 4B).

Figure 4. Effect of ICT on muscle fiber type distribution.

Figure 4

Open in a new tab

(A) Representative images of cross-sections from mid-belly soleus muscle immunostained for MHC I (blue), MHC IIa (green) and hybrid (MHC I/IIa, light green) muscle fiber. Scale bar, 100 μM. (B) Distribution of MHC isoforms in soleus muscle. Data are presented as mean ± SEM. N = 10. Proportion of MHC I fiber, *for P < 0.05 vs. Baseline. #for P < 0.05 vs. HS. + for P < 0.05 vs. High-ICT+Wort. Each sample was assessed in triplicate.

Effect of ICT treatment on muscle function

The influence of ICT treatment on muscle functional properties was evaluated with in vitro muscle functional testing. The twitch force and specific force in the HS Group were significantly lower than those in the Baseline Group. Both parameters were moderately higher in the Low-ICT Group (P > 0.05), but significantly higher in the High-ICT Group compared to the HS Group. The twitch force in the High-ICT was still lower than that in the Baseline Group, whereas the specific force in the High-ICT Group was not significantly different from that in the Baseline Group. The contraction time and half relaxation time were shorter in the HS Group than those in the Baseline Group, while both parameters were prolonged in the High-ICT Group, but still shorter compared to the Baseline Group. Wortmannin treatment led to a moderately lower twitch force and specific force (P > 0.05) and significantly shorter contraction time and half relaxation time compared to the High-ICT Group. All the parameters in the three wortmannin treatment groups were not significantly different from those in the HS Group (Fig. 5).

Figure 5. Effect of ICT on muscle function parameters.

Figure 5

Open in a new tab

(A) Representative curves of Twitch force (upper two rows) and Maximal isometric force (lower two rows) in each group. (B) Twitch force, mN; (C) Specific force, mN/mm2; (D) Twitch contraction time, sec; (E) Half relaxation time, sec. Data are presented as mean ± SEM. N = 10. *for P < 0.05 vs. Baseline. #for P < 0.05 vs. HS. + for P < 0.05 vs. High-ICT+Wort. Each sample was assessed in triplicate.

Effect of ICT treatment on protein synthesis markers

The influence of ICT treatment on the phosphorylation state (activation) of PI3K-110 and its downstream proteins (Akt, mTOR, p70S6K, 4EBP1) that contribute to the protein synthesis in soleus muscle was determined by western blotting. Compared to the Baseline Group, the phosphorylation levels of above markers were significantly lower in the HS Group. The phosphorylation levels of the proteins in the Low-ICT Group were a little higher than those in the HS Group (P > 0.05). The High-ICT Group demonstrated significantly higher phosphorylation levels than those in the HS Group, which were significantly attenuated by the wortmannin treatment. The phosphorylation levels of those proteins in the three wortmannin-treated groups were not statistically different from those in the HS Group (Fig. 6).

Figure 6. Effect of ICT on protein synthesis markers.

Figure 6

Open in a new tab

(A) The expression levels of phosphorylated and total proteins (PI3K-p110, Akt, mTOR, p70S6K and 4EBP1) in soleus muscle detected by western blotting. (B) Quantification of above marker proteins in soleus muscle. Data are presented as mean ± SEM. N = 10. *for P < 0.05 vs. Baseline. #for P < 0.05 vs. HS. + for P < 0.05 vs. High-ICT+Wort. GAPDH served as the endogenous control. Each sample was assessed in triplicate.

Effect of ICT treatment on protein degradation markers

FOXO1 and FOXO3a would be dephosphorylated and enter into the nucleus when Akt was inactivated, then activate atrophy-induced genes, such as muscle-specific E3 ubiquitin ligases Atrogin-1 and MuRF-1 and trigger protein degradation19. The cellular distribution of FOXO1/FOXO3a proteins and the mRNA levels of Atrogin-1 and MuRF-1 were detected by western blotting and real-time PCR, respectively. The expression levels of FOXO1 and FOXO3a in nuclei fraction were significantly higher in the HS Group compared to the Baseline Group. The expression levels in the Low-ICT Group were slightly lower than those in the HS Group (P >0.05), while the levels in the High-ICT Group were significantly lower than those in the HS Group. Wortmannin treatment led to the significantly higher levels of FOXO1 and FOXO3a in nuclei fraction compared to the High-ICT Group. No differences were found between the Wort Groups and the HS Group. Similar data were also found in the mRNA levels of Atrogin-1 and MuRF-1 (Fig. 7).

Figure 7. Effect of ICT on protein degradation markers.

Figure 7

Open in a new tab

(A) The protein levels of FOXO1 and FOXO3a in total cell (left) and nuclei (right) examined by western blotting. (B) Quantification of the proteins levels of FOXO1 (left) and FOXO3a (right). (C) The mRNA levels of Atrogin-1 (left) and MuRF-1(right) in soleus muscle detected by real-time PCR. Data are presented as mean ± SEM. N = 10. *for P < 0.05 vs. Baseline. #for P < 0.05 vs. HS. + for P < 0.05 vs. High-ICT+Wort. GAPDH served as the endogenous control. Each sample was assessed in triplicate.

Discussion

To our knowledge, the current study is the first one to demonstrate that ICT could require PI3K/Akt signaling to attenuate the skeletal muscle atrophy induced by mechanical unloading in a dose-dependent manner in adult rats.

After 28-day HS, declines of 42.7% in muscle mass and 54.7% in muscle fiber CSA were observed, which were consistent with the previous findings11. An attenuation effect of ICT treatment on muscle atrophy during mechanical unloading was demonstrated. The high dose ICT treated animals showed 25.4% higher in muscle mass and 48.1% higher in muscle fiber CSA compared to the HS animals, the low dose ICT treatment showed moderate attenuation effect. It indicated that ICT could attenuate the decreases of muscle mass and muscle CSA induced by mechanical unloading in a dose-dependent manner.

As an antigravity muscle, soleus muscle consists of mostly type I (slow-twitch) fibers33. During unloading-induced muscle atrophy, a slow-to-fast fiber type (type I to II) transition was noticed in our study, which was consistent with the previous reports5,34. The low dose ICT treatment moderately attenuated the transition compared to the HS Group, whereas the high dose ICT significantly attenuated the transition in the current study. Consistently, the muscle functional analysis showed that the twitch contraction time, half relaxation time, twitch peak force and tetanic peak force decreased during unloading-induced muscle atrophy, which were all attenuated by the ICT treatment. These evidences indicated that ICT treatment could attenuate this slow-to-fast fiber type transition and the decrease of muscle function in a dose-dependent manner.

Inconsistently, the specific force in the High-ICT Group was close to that of the Baseline Group, indicating ICT treatment could prevent the decrease of the specific force during unloading-induced muscle atrophy. The specific force reflects the functional quality of the muscle, maximum specific force in single skeletal muscle fibers is dependent on the number of cross bridges per half sarcomere, the average force per cross bridge, and the fraction of cross bridges in the force generating state35. Regarding to the incomplete prevention effect of ICT on the structural features including the muscle mass, muscle fiber CSA and muscle fiber type distribution during mechanical unloading, the inconsistence between the structural and functional consequences might be due to the involvement of more than one mechanism, for example, the regulation of ICT on the excitation-contraction (E-C) coupling properties during unloading-induced muscle atrophy.

Furthermore, the safety evaluation showed no dominant side effects on blood biochemical parameters and major organs during the ICT treatment. ICT could be a potential candidate for counteracting muscle atrophy induced by mechanical unloading.

PI3K/Akt signaling pathway is critical for regulating the balance between protein synthesis and degradation. Activation of PI3K leads to activation of the serine/threonine kinase Akt, which in turn phosphorylates and activates its downstream proteins (mTOR, p70S6K, 4EBP1 and eIF4E) and result in increased protein synthesis36,37. Our in vitro study showed that ICT treatment could promote the expression of PI3K/Akt signaling markers. Consistent with previous reports38,39, the phosphorylation levels of PI3K at p110 catalytic subunit, Akt and the downstream markers related to protein synthesis decreased after 28-day HS, which could be attenuated by ICT treatment in a dose-dependent manner in our study. On the other hand, PI3K/Akt pathway also could inhibit the process of protein degradation19. Deactivation of Akt would lead to relocation of FOXO family transcription factors into the nucleus and activates atrophy-induced genes, such as muscle-specific E3 ubiquitin ligases Atrogin-1/MAFbx and MuRF-1, which contributes to the protein degradation during the progression of muscle atrophy19,40,41. In our study, ICT treatment could attenuate the relocation of FOXO1 and FOXO3a to the nucleus and then depress the elevation of mRNA expression of Atrogin-1 and MuRF-1. Taken together, ICT could counteract the reduction in the activity of PI3K/Akt signaling pathway during unloading.

Wortmannin is a specific PI3K inhibitor, which binds to the p110 catalytic subunit, noncompetitively and irreversibly inhibiting the enzyme42,43. The expression level of phosphorylated p110 catalytic subunit of PI3K in the ICT+Wort Group in vitro (High-ICT+Wort Group in vivo) was significantly lower than that in the ICT Group in vitro (High-ICT Group in vivo). Consistently, the counteraction effect of ICT treatment on unloading-induced muscle atrophy could also be abolished by wortmannin, as evidenced by the lower muscle mass, reduced muscle fiber CSA, more slow-to-fast transition and decreased muscle function in the High-ICT+Wort Group when compared to the High-ICT Group. These evidences indicated that PI3K at p110 catalytic subunit in the PI3K/Akt signaling was required by ICT to attenuate unloading-induced muscle atrophy.

Theoretically, the muscle atrophy should be more serious once the wortmannin treatment and HS were combined. Interestingly, there was no significant difference in all the examined parameters between the Wort Group and the HS Group. PI3K/Akt signaling pathway is crucial for regulating both protein synthesis and degradation during muscle atrophy. Although there are other signaling pathways contributing to muscle atrophy as well44,45,46, PI3K/Akt signaling pathway might play the dominant role during the muscle atrophy induced by mechanical unloading47. There’s no significant difference between the activation levels of PI3K in HS group and HS plus wortmannin group, indicating wortmannin treatment plus HS does not have a superimposition effect. It implied that PI3K/Akt signaling pathway inhibition might be mainly required by HS to do harm to muscle.

In summary, our findings demonstrated that ICT treatment had an attenuation effect on mechanical unloading-induced muscle atrophy in a dose-dependent manner and PI3K/Akt signaling was required by ICT to exert its therapeutic effect.

Materials & Methods

Cell Culture

C2C12 cells from the American Type Culture Collection (ATCC) were maintained in Dulbecco’s Modified Eagle Medium (DMEM, Invitrogen) which containing 10% FBS (Gibco) and 1% penicillin and streptomycin (Invitrogen) under standard cell culture conditions of 5% CO2 and 95% humidity. ICT (U-sea Biotech, Shanghai, China) was supplemented at concentrations of 5 μM, 10 μM or 20 μM. After 24 hours incubation, cells were collected and lysed for western blotting and real-time PCR analysis. In addition, C2C12 cells were incubated with 20 μM ICT for 1, 3, 5 and 7 days. CCK-8 assay (Sigma-Aldrich, Saint Louis, MO, USA) and morphology examination were performed according to the manufacturer’s instructions. The expression levels of MyoD and myogenin in C2C12 cells were determined by western blotting. In wortmannin experiments, C2C12 cells were pre-incubated with wortmannin (Cayman Chemical, Ann Arbor, MI, USA) at the concentration of 5 nM for 1 hour before the ICT treatment (20 μM). Cells cultured in the routine medium only throughout experiment served as the control.

Animal model and group designation

Eighty 3-month old male SD rats were recruited and divided into the following eight groups (n = 10 per group): 1) Baseline Group: sacrificed before HS; 2) Age-matched Control Group: weight bearing throughout experiment; 3) HS Group: HS plus vehicles served as treatment control; 4) Low-ICT Group: HS plus ICT at low dose (80mg/kg/day); 5) High-ICT Group: HS plus ICT at high dose (120mg/kg/day); 6) Low-ICT+Wort Group: HS plus Low-ICT plus Wortmannin (15 μg/kg/day); 7) High-ICT+Wort Group: HS plus High-ICT plus Wortmannin; 8) Wort Group: HS plus Wortmannin. ICT was orally administered daily throughout HS. Wortmannin was intraperitoneally injected daily throughout HS48. All the procedures used in animal studies were carried out in accordance with the Animal Experimentation Regulations at The Chinese University of Hong Kong and The Hong Kong Code of Practice for Care and Use of Animals for Experimental Purposes. All experimental protocols were reviewed and approved by the Animal Experimentation Ethics Committee of The Chinese University of Hong Kong (Ref No. 12/019/GRF-5). At the end of hindlimb suspension, all the animals were sacrificed with overdose of sodium pentobarbital (35mg/kg) (Sigma-Aldrich, Saint Louis, MO, USA). One side of soleus muscle was subjected to the in vitro functional testing and subsequent histology and immunohistochemistry analysis. The other side of soleus muscle was quickly frozen in liquid nitrogen for protein and total RNA extraction followed by the western blotting and real-time PCR analysis, respectively. For safety evaluation, the blood sample was obtained from the HS, Low-ICT and High-ICT groups in order to determine the biochemical parameters. The heart, liver, kidneys, lungs and brain from the above three groups were dissected out, washed with saline and conserved in 10% formalin for histological analysis.

Hindlimb suspension procedure

The animals were subjected to hindlimb suspension for 28 days following established procedure11,49. Briefly, a strip of adhesive tape (15 cm × 0.5 cm) was applied to the animal’s tail, which was suspended by passing the tape through a fish-line swivel that was attached to a metal bar on the top of the cage. This allowed the forelimbs to have contact with the grid floor and allowed the animals to move around the cage for free access to food and water. The suspension height was adjusted to prevent the hindlimbs from touching any supporting surface while maintaining a suspension angle of approximately 30°. The animal’s overall appearance, drinking and eating habits and tail were monitored four times per day. The distal tip of the tail was examined to ensure that the procedure did not occlude blood flow to the tail by maintaining the tail pink.

In vitro muscle functional testing

The in vitro muscle functional testing was performed following our established protocol50,51. Dissected muscle with intact tendons was mounted in a specific chamber bathed with 95%O2/5%CO2-bubbled Krebs’ solution (In Vitro Muscle Test System 1205, Aurora Scientific Inc., Aurora, ON, Canada). One end of the tendon was attached to a hook connected to the lever arm of a position feedback motor, and the other end was attached to a force transducer. The muscle was adjusted to the optimum length (L0) at which the maximal twitch force was produced. The muscle was stimulated with 0.5 ms pulses of supramaximal intensity through two platinum plates that were parallel to the muscle. Peak twitch force at 1Hz and peak tetanic force at 100Hz for 400 ms were recorded, and twitch contraction time and half relaxation time were calculated with the ASI Dynamic Muscle Control Software (DMC v5.1 beta, Aurora Scientific Inc.). Specific force was expressed as peak tetanic force normalized to the muscle physical cross-sectional area52.

Histology and immunohistochemistry

The dissected soleus muscles were snap frozen in liquid nitrogen-cooled isopentane and then embedded in OCT medium. Serial cross-sections (6 μM thickness) were cut from the mid-belly of the muscles on a cryostat at −20 °C for histological and immunohistochemical staining. Hematoxylin and eosin staining was performed on sections to examine the general morphology and to determine the mean cross-sectional area (CSA) of the muscle fiber.

For immunohistochemical staining, the cryosections were fixed in cold acetone (4 °C) for 10 min and then incubated for 60 min in a 1% bovine serum albumin (BSA)/PBS solution to block non-specific binding. The sections were then incubated overnight at 4 °C with antibody cocktail of primary antibodies against MHC I (BA-F8 1:50, DSHB, University of Iowa, IA, USA), MHC IIa (SC-71 1:600, DSHB), MHC IId/x/IIb (BF-F3 1:100, DSHB). Following three washes in PBS, the sections were incubated with cocktail of Alexa Fluor 350 IgG2b, Alexa Fluor 488 IgG1 and Alexa Fluor 555 IgM (1:500, Invitrogen) for 60 min. The sections were again washed in PBS, and mounted in Mowiol mounting medium (Merck KGaA, Darmstadt, Germany). Slides were visualized with an Axio Observer Z1 microscope (Carl Zeiss, Jena, Germany) using conventional widefield fluorescence microscopy as well as optical sectioning via structured-illumination fluorescence microscopy (Apotome, Carl Zeiss). Area proportion of each fiber type was determined.

Heart, liver, kidneys, lungs and brain were conserved in 10% formalin for histopathological studies. Tissues were processed by conventional techniques. The paraffine embedded sections of 4–5 μm thickness were prepared with the rotary microtome, stained with hematoxylin and eosin for microscopic examination.

Western blot analysis

It was to test the activation of PI3K/Akt signaling markers related to protein synthesis and myogenic markers, protein extracted from cell or muscle homogenates was quantified using Bradford Assay (Bio-Rad). Protein samples were separated by SDS-PAGE and transferred into nitrocellulose membranes (Perkin Elmer). After blocking with 5% nonfat dry milk in tris buffered saline (TBS) containing 0.05% Tween 20, the membranes were then probed with primary antibodies against total and phospho-PI3K p110 (Tyr 485) (Santa Cruz), total and phospho-Akt (Ser473), total and phospho-mTOR (Ser2481), total and phospho-p70S6K (Thr389), total and phospho-4EBP1 (Thr37/46) (Cell Signaling Technology, Beverly, MA, USA), MyoD and myogenin (Santa Cruz). Membranes were incubated with specific horseradish peroxidase-conjugated secondary antibodies (Santa Cruz). Immunodetection was performed using enhanced chemiluminescence consistent with the manufacturer’s protocol (BioRad). Membranes were also probed with an antibody for GAPDH (Santa Cruz) to serve as a loading control.

It was to test the cellular distribution of FOXO1 and FOXO3a related to protein degradation, frozen muscle pieces were fractionated into nuclear fraction using a Subcellular Proteo-Extract proteome kit (EBD Biosciences). The proteins extracted from nuclear fraction and total cell were then subjected to the western blot analysis mentioned above.

Real-time PCR analysis

Total RNA of soleus muscles was extracted using SV total RNA isolation system (Promega), and cDNA was synthesized from 0.5 μg total RNA of each soleus sample using SuperScript III First-Strand Synthesis Kit (Invitrogen) according to manufacturer’s instructions. TaqMan® gene expression assay with primers and MGB probes that are specific for rat Atrogin-1 and MuRF-1 (Assay ID: AF441120 for Atrogin-1 and AY059627 for MuRF-1; Applied Biosystems) were used for real-time PCR analysis. The amplification was performed in a real-time PCR system (StepOnePlus, Applied Biosystems). GAPDH was used as an endogenous control for normalization. Each sample was assessed in triplicate. Relative changes in Atrogin-1 and MuRF-1 gene expression were determined using the 2−ΔΔCt (normalized expression ratio) method of analysis.

Blood biochemical parameters evaluation

Blood samples without anticoagulant were centrifuged (1000 rpm, 30 min) and the obtained serum was kept at −4 °C for four days, at most, before the biochemical parameters determination. Serum creatinine, urea, uric acid, total protein, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase were determined. Creatinine and total proteins were measured by colorimetric assay, while the other parameters were measured by enzymatic colorimetric assay. The kits used in these tests were obtained from Abcam (UK) and the analysis was carried out using a Multiparametric Autoanalyzer (Lisabio B652, USA).

Data analysis

The results were presented as mean ± standard error of the means (SEM). The data were analyzed by one way analysis of variance (ANOVA). LSD post-hoc test was made for multiple comparisons among all eight groups to determine the differences at a significance level of P < 0.05.

Additional Information

How to cite this article: ZHANG, Z.-K. et al. Icaritin requires Phosphatidylinositol 3 kinase (PI3K)/Akt signaling to counteract skeletal muscle atrophy following mechanical unloading. Sci. Rep. 6, 20300; doi: 10.1038/srep20300 (2016).

Supplementary Material

Supplementary Information
srep20300-s1.doc (1.1MB, doc)

Acknowledgments

This project was funded by grant from National Natural Science Foundation of China (81201406), and grant from Hong Kong Research Grants Council Early Career Scheme (489213), and the Direct Grant for Research from the Chinese University of Hong Kong (4054138).

Footnotes

Author Contributions B.T.Z., G.Z. and A.L. designed the study and revised the manuscript; Z.K.Z. and J.L.I. conducted cell culture, animal experiments, in vitro muscle functional testing, immunohistochemical staining, western blotting and real-time PCR and drafted the manuscript; J.L. and B.S.G. conducted western blotting and data analysis; B.T.Z., G.Z. and A.L. approved final version of the manuscript and took responsibility for the integrity of the data.

References

  1. Booth F. W. Effect of limb immobilization on skeletal muscle. Journal of applied physiology: respiratory, environmental and exercise physiology 52, 1113–1118 (1982). [DOI] [PubMed] [Google Scholar]
  2. Berg H. E., Larsson L. & Tesch P. A. Lower limb skeletal muscle function after 6 wk of bed rest. Journal of applied physiology 82, 182–188 (1997). [DOI] [PubMed] [Google Scholar]
  3. Kim S. J. et al. Electromechanical stimulation ameliorates inactivity-induced adaptations in the medial gastrocnemius of adult rats. Journal of applied physiology 103, 195–205 (2007). [DOI] [PubMed] [Google Scholar]
  4. Thomason D. B. & Booth F. W. Atrophy of the soleus muscle by hindlimb unweighting. Journal of applied physiology 68, 1–12 (1990). [DOI] [PubMed] [Google Scholar]
  5. Fitts R. H., Riley D. R. & Widrick J. J. Physiology of a microgravity environment invited review: microgravity and skeletal muscle. Journal of applied physiology 89, 823–839 (2000). [DOI] [PubMed] [Google Scholar]
  6. Jackman R. W. & Kandarian S. C. The molecular basis of skeletal muscle atrophy. American journal of physiology. Cell physiology 287, C834–843 (2004). [DOI] [PubMed] [Google Scholar]
  7. Aguirre J. I. et al. Osteocyte apoptosis is induced by weightlessness in mice and precedes osteoclast recruitment and bone loss. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 21, 605–615 (2006). [DOI] [PubMed] [Google Scholar]
  8. Metter E. J., Talbot L. A., Schrager M. & Conwit R. Skeletal muscle strength as a predictor of all-cause mortality in healthy men. The journals of gerontology. Series A, Biological sciences and medical sciences 57, B359–365 (2002). [DOI] [PubMed] [Google Scholar]
  9. Strawbridge W. J., Shema S. J., Balfour J. L., Higby H. R. & Kaplan G. A. Antecedents of frailty over three decades in an older cohort. The journals of gerontology. Series B, Psychological sciences and social sciences 53, S9–16 (1998). [DOI] [PubMed] [Google Scholar]
  10. Glover E. I. & Phillips S. M. Resistance exercise and appropriate nutrition to counteract muscle wasting and promote muscle hypertrophy. Current opinion in clinical nutrition and metabolic care 13, 630–634 (2010). [DOI] [PubMed] [Google Scholar]
  11. Zhang B. T. et al. The effects of low frequency electrical stimulation on satellite cell activity in rat skeletal muscle during hindlimb suspension. BMC cell biology 11, 87 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Alzghoul M. B., Gerrard D., Watkins B. A. & Hannon K. Ectopic expression of IGF-I and Shh by skeletal muscle inhibits disuse-mediated skeletal muscle atrophy and bone osteopenia in vivo. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 18, 221–223 (2004). [DOI] [PubMed] [Google Scholar]
  13. Gregory C. M., Vandenborne K., Huang H. F., Ottenweller J. E. & Dudley G. A. Effects of testosterone replacement therapy on skeletal muscle after spinal cord injury. Spinal cord 41, 23–28 (2003). [DOI] [PubMed] [Google Scholar]
  14. Murphy K. T., Cobani V., Ryall J. G., Ibebunjo C. & Lynch G. S. Acute antibody-directed myostatin inhibition attenuates disuse muscle atrophy and weakness in mice. Journal of applied physiology 110, 1065–1072 (2011). [DOI] [PubMed] [Google Scholar]
  15. Picquet F., De-Doncker L. & Falempin M. Enhancement of hybrid-fiber types in rat soleus muscle after clenbuterol administration during hindlimb unloading. Canadian journal of physiology and pharmacology 82, 311–318 (2004). [DOI] [PubMed] [Google Scholar]
  16. Lynch G. S., Schertzer J. D. & Ryall J. G. Therapeutic approaches for muscle wasting disorders. Pharmacology & therapeutics 113, 461–487 (2007). [DOI] [PubMed] [Google Scholar]
  17. Morissette M. R. et al. Myostatin regulates cardiomyocyte growth through modulation of Akt signaling. Circulation research 99, 15–24 (2006). [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Schiaffino S., Dyar K. A., Ciciliot S., Blaauw B. & Sandri M. Mechanisms regulating skeletal muscle growth and atrophy. The FEBS journal 280, 4294–4314 (2013). [DOI] [PubMed] [Google Scholar]
  19. Kandarian S. C. & Jackman R. W. Intracellular signaling during skeletal muscle atrophy. Muscle & nerve 33, 155–165 (2006). [DOI] [PubMed] [Google Scholar]
  20. Wu C., Sheng Y., Zhang Y., Zhang J. & Guo B. Identification and characterization of active compounds and their metabolites by high-performance liquid chromatography/Fourier transform ion cyclotron resonance mass spectrometry after oral administration of a herbal extract of Epimedium koreanum Nakai to rats. Rapid communications in mass spectrometry : RCM 22, 2813–2824 (2008). [DOI] [PubMed] [Google Scholar]
  21. Zhang G., Qin L. & Shi Y. Epimedium-derived phytoestrogen flavonoids exert beneficial effect on preventing bone loss in late postmenopausal women: a 24-month randomized, double-blind and placebo-controlled trial. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 22, 1072–1079 (2007). [DOI] [PubMed] [Google Scholar]
  22. Zhang G. et al. Constitutional flavonoids derived from Epimedium dose-dependently reduce incidence of steroid-associated osteonecrosis not via direct action by themselves on potential cellular targets. PloS one 4, e6419 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Zhang G. et al. A novel semisynthesized small molecule icaritin reduces incidence of steroid-associated osteonecrosis with inhibition of both thrombosis and lipid-deposition in a dose-dependent manner. Bone 44, 345–356 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Zeng K. W., Ko H., Yang H. O. & Wang X. M. Icariin attenuates beta-amyloid-induced neurotoxicity by inhibition of tau protein hyperphosphorylation in PC12 cells. Neuropharmacology 59, 542–550 (2010). [DOI] [PubMed] [Google Scholar]
  25. Chen M. F. et al. Icaritin induces growth inhibition and apoptosis of human prostatic smooth muscle cells in an estrogen receptor-independent manner. Amino acids 38, 1505–1513 (2010). [DOI] [PubMed] [Google Scholar]
  26. Zhang G. et al. Flavonoids derived from herbal Epimedium Brevicornum Maxim prevent OVX-induced osteoporosis in rats independent of its enhancement in intestinal calcium absorption. Bone 38, 818–825 (2006). [DOI] [PubMed] [Google Scholar]
  27. Wu J. et al. Icaritin attenuates cigarette smoke-mediated oxidative stress in human lung epithelial cells via activation of PI3K-AKT and Nrf2 signaling. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 64, 307–313 (2014). [DOI] [PubMed] [Google Scholar]
  28. Zhang D. et al. Icariin Prevents Amyloid Beta-Induced Apoptosis via the PI3K/Akt Pathway in PC-12 Cells. Evidence-based complementary and alternative medicine : eCAM 2015, 235265 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Tang Y. et al. Icariin promotes angiogenic differentiation and prevents oxidative stress-induced autophagy in endothelial progenitor cells. Stem cells 33, 1863–1877 (2015). [DOI] [PubMed] [Google Scholar]
  30. Zhai Y. K. et al. Icariin stimulates the osteogenic differentiation of rat bone marrow stromal cells via activating the PI3K-AKT-eNOS-NO-cGMP-PKG. Bone 66, 189–198 (2014). [DOI] [PubMed] [Google Scholar]
  31. Xu C. Q. et al. Icariin attenuates LPS-induced acute inflammatory responses: involvement of PI3K/Akt and NF-kappaB signaling pathway. European journal of pharmacology 642, 146–153 (2010). [DOI] [PubMed] [Google Scholar]
  32. Glass D. J. PI3 kinase regulation of skeletal muscle hypertrophy and atrophy. Current topics in microbiology and immunology 346, 267–278 (2010). [DOI] [PubMed] [Google Scholar]
  33. Soukup T., Zacharova G. & Smerdu V. Fibre type composition of soleus and extensor digitorum longus muscles in normal female inbred Lewis rats. Acta histochemica 104, 399–405 (2002). [DOI] [PubMed] [Google Scholar]
  34. Canon F., Goubel F. & Guezennec C. Y. Effects of chronic low frequency stimulation on contractile and elastic properties of hindlimb suspended rat soleus muscle. European journal of applied physiology and occupational physiology 77, 118–124 (1998). [DOI] [PubMed] [Google Scholar]
  35. Geiger P. C., Cody M. J., Macken R. L. & Sieck G. C. Maximum specific force depends on myosin heavy chain content in rat diaphragm muscle fibers. Journal of applied physiology 89, 695–703 (2000). [DOI] [PubMed] [Google Scholar]
  36. Glass D. J. Molecular mechanisms modulating muscle mass. Trends in molecular medicine 9, 344–350 (2003). [DOI] [PubMed] [Google Scholar]
  37. Sartorelli V. & Fulco M. Molecular and cellular determinants of skeletal muscle atrophy and hypertrophy. Science’s STKE : signal transduction knowledge environment 2004, re11 (2004). [DOI] [PubMed] [Google Scholar]
  38. Bodine S. C. et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nature cell biology 3, 1014–1019 (2001). [DOI] [PubMed] [Google Scholar]
  39. Hornberger T. A., Hunter R. B., Kandarian S. C. & Esser K. A. Regulation of translation factors during hindlimb unloading and denervation of skeletal muscle in rats. American journal of physiology. Cell physiology 281, C179–187 (2001). [DOI] [PubMed] [Google Scholar]
  40. Glass D. J. Skeletal muscle hypertrophy and atrophy signaling pathways. The international journal of biochemistry & cell biology 37, 1974–1984 (2005). [DOI] [PubMed] [Google Scholar]
  41. Senf S. M., Dodd S. L. & Judge A. R. FOXO signaling is required for disuse muscle atrophy and is directly regulated by Hsp70. American journal of physiology. Cell physiology 298, C38–45 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Walker E. H. et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 6, 909–919 (2000). [DOI] [PubMed] [Google Scholar]
  43. Powis G. et al. Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer research 54, 2419–2423 (1994). [PubMed] [Google Scholar]
  44. Gordon S. E., Fluck M. & Booth F. W. Selected Contribution: Skeletal muscle focal adhesion kinase, paxillin, and serum response factor are loading dependent. Journal of applied physiology 90, 1174-1183; discussion 1165 (2001). [DOI] [PubMed] [Google Scholar]
  45. Kang C. & Ji L. L. Muscle immobilization and remobilization downregulates PGC-1alpha signaling and the mitochondrial biogenesis pathway. Journal of applied physiology 115, 1618–1625 (2013). [DOI] [PubMed] [Google Scholar]
  46. Carlson C. J., Booth F. W. & Gordon S. E. Skeletal muscle myostatin mRNA expression is fiber-type specific and increases during hindlimb unloading. The American journal of physiology 277, R601–606 (1999). [DOI] [PubMed] [Google Scholar]
  47. Zhang P., Chen X. & Fan M. Signaling mechanisms involved in disuse muscle atrophy. Medical hypotheses 69, 310–321 (2007). [DOI] [PubMed] [Google Scholar]
  48. Wolfrum S. et al. Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arteriosclerosis, thrombosis, and vascular biology 24, 1842–1847 (2004). [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Zhang B. T., Yeung S. S., Cheung K. K., Chai Z. Y. & Yeung E. W. Adaptive responses of TRPC1 and TRPC3 during skeletal muscle atrophy and regrowth. Muscle & nerve 49, 691–699 (2014). [DOI] [PubMed] [Google Scholar]
  50. Zhang B. T., Yeung S. S., Allen D. G., Qin L. & Yeung E. W. Role of the calcium-calpain pathway in cytoskeletal damage after eccentric contractions. Journal of applied physiology 105, 352–357 (2008). [DOI] [PubMed] [Google Scholar]
  51. Zhang B. T. et al. Pathways of Ca(2)(+) entry and cytoskeletal damage following eccentric contractions in mouse skeletal muscle. Journal of applied physiology 112, 2077–2086 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Eng C. M. et al. Scaling of muscle architecture and fiber types in the rat hindlimb. J Exp Biol 211, 2336–2345 (2008). [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Information
srep20300-s1.doc (1.1MB, doc)

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES